CAS: 15533-09-2
| Marchio | Dati del prodotto | Purezza | Fascia di prezzo | Consegna prevista |
|---|---|---|---|---|
 | 2-Hydroxy-benzoic Acid [1-(2-Hydroxyphenyl)ethylidene]hydrazide REF: IN-DA01EPPECAS: 15533-09-2 | 97% | Prezzo su richiesta | Mar 10 Dic 24 |
 | 2-Hydroxy-benzoic acid [1-(2-hydroxyphenyl)ethylidene]hydrazide REF: 3D-QAA53309CAS: 15533-09-2 | Min. 95% | Prezzo su richiesta | Mar 21 Gen 25 |
 | Compound C108 REF: TM-T38387CAS: 15533-09-2 | 99.77% | 45,00 €~1.254,00 € | Mar 28 Gen 25 |
![2-Hydroxy-benzoic Acid [1-(2-Hydroxyphenyl)ethylidene]hydrazide](https://static.cymitquimica.com/products/IN/thumb/DA01EPPE.jpg)
2-Hydroxy-benzoic Acid [1-(2-Hydroxyphenyl)ethylidene]hydrazide
CAS:15533-09-2
Formula:
C15H14N2O3
Purezza:
97%
Peso molecolare:
270.2833
Ref: IN-DA01EPPE
| 1mg | 101,00 € | ||
| 5mg | 210,00 € | ||
| 10mg | 472,00 € | ||
| 25mg | Prezzo su richiesta | ||
| 50mg | Prezzo su richiesta | ||
| 100mg | Prezzo su richiesta |
Consegna stimata in Stati Uniti, il Martedì 10 Dicembre 2024
![2-Hydroxy-benzoic acid [1-(2-hydroxyphenyl)ethylidene]hydrazide](https://static.cymitquimica.com/products/3D/thumb/QAA53309.jpg)
2-Hydroxy-benzoic acid [1-(2-hydroxyphenyl)ethylidene]hydrazide
CAS:15533-09-2
2-Hydroxy-benzoic acid (2HB) is a functional compound that inhibits the growth of cancer cells. It …
Formula:
C15H14N2O3
Purezza:
Min. 95%
Peso molecolare:
270.28 g/mol
Ref: 3D-QAA53309
| 10mg | Prezzo su richiesta | ||
| 25mg | Prezzo su richiesta | ||
| 50mg | Prezzo su richiesta |
Consegna stimata in Stati Uniti, il Martedì 21 Gennaio 2025
Compound C108
CAS:15533-09-2
Compound C108 is an inhibitor of GTPase-activating protein SH3 domain-binding protein 2 (G3BP2).
Formula:
C15H14N2O3
Purezza:
99.77%
Colore e forma:
Liquid
Peso molecolare:
270.28
Ref: TM-T38387
| 1mg | 45,00 € | ||
| 5mg | 88,00 € | ||
| 10mg | 128,00 € | ||
| 25mg | 247,00 € | ||
| 50mg | 393,00 € | ||
| 100mg | 584,00 € | ||
| 500mg | 1.254,00 € | ||
| 1mL*10mM (DMSO) | 123,00 € |
Consegna stimata in Stati Uniti, il Martedì 28 Gennaio 2025
